XLO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is low on a book/sales basis, but meaningless on an earnings basis.
- Low Price/Sales (1.12)
- Price/Book near 1.0
- Negative Forward P/E
- No Graham Number due to lack of earnings
Growth is high, but execution relative to estimates is very poor.
- Hyper-growth in revenue
- Positive EPS growth trajectory
- Massive earnings surprises to the downside
- Unproven path to profitability
Historical price performance is catastrophic.
- 5-year return of -96.2%
- Consistent quarterly losses
Liquidity is the only strength; operational health is poor.
- Low Debt/Equity
- Strong Quick Ratio (2.53)
- Piotroski F-Score 4/9
- Negative ROA and ROE
Non-dividend paying biotech.
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for XLO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
XLO
Xilio Therapeutics, Inc.
Primary
|
-96.2% | -80.8% | -23.8% | -21.7% | +1.2% | +1.4% |
|
ELUT
Elutia Inc.
Peer
|
-91.4% | -20.8% | -53.7% | +28.2% | -2.6% | +4.6% |
|
SCLX
Scilex Holding Company
Peer
|
-98.0% | -98.6% | +14.6% | -46.0% | -10.6% | +1.5% |
|
SCYX
SCYNEXIS, Inc.
Peer
|
-85.1% | -65.7% | +22.8% | +47.0% | +23.3% | +11.0% |
|
NTRB
Nutriband Inc.
Peer
|
-28.9% | +17.2% | -16.9% | -45.8% | +7.4% | +4.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
XLO
Xilio Therapeutics, Inc.
|
BEARISH | $48.98M | - | -132.5% | -80.1% | $8.47 | |
|
ELUT
Elutia Inc.
|
BULLISH | $48.77M | - | -% | 434.2% | $1.14 | Compare |
|
SCLX
Scilex Holding Company
|
BEARISH | $48.53M | - | -% | -% | $6.9 | Compare |
|
SCYX
SCYNEXIS, Inc.
|
BULLISH | $49.58M | - | -16.5% | -41.8% | $1.11 | Compare |
|
NTRB
Nutriband Inc.
|
BEARISH | $49.67M | - | -136.1% | -% | $4.08 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | BRENNAN KEVIN M | Officer | Sale | 1,826 | $1,174 |
| 2026-01-02 | FRANKENFIELD CHRISTOPHER JAMES | Chief Financial Officer | Sale | 7,030 | $4,522 |
| 2025-12-31 | RUSSO RENE PHARM.D. | Chief Executive Officer | Stock Award | 44,250 | - |
| 2025-12-31 | BRENNAN KEVIN M | Officer | Stock Award | 5,000 | - |
| 2025-12-31 | FRANKENFIELD CHRISTOPHER JAMES | Chief Financial Officer | Stock Award | 19,375 | - |
| 2025-12-31 | LUPTAKOVA KATARINA M.D. | Officer | Stock Award | 16,625 | - |
| 2025-11-26 | GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Option Exercise | 13,335,000 | $9,999,916 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning XLO from our newsroom.